What's Happening?
Aulos Bioscience has presented new Phase 2 data for its lead immune-activating antibody therapeutic, imneskibart (AU-007), at the Society for Immunotherapy of Cancer's 40th Annual Meeting. The data demonstrate sustained anti-tumor activity in melanoma
patients who progressed on prior doublet CPI therapy and early signals of objective responses in NSCLC patients. Imneskibart, combined with low-dose aldesleukin, shows unique activity in the IL-2 class, reinforcing its competitive advantages.
Why It's Important?
The promising Phase 2 results highlight imneskibart's potential to achieve deep and durable tumor regressions in heavily pre-treated melanoma and NSCLC patients. By expanding T effector and natural killer cells while reducing regulatory T cells, imneskibart offers a differentiated approach within the IL-2 class. The therapy's success could lead to new treatment options for patients with CPI-refractory cancers, improving outcomes and expanding the use of IL-2 therapeutics in oncology.
What's Next?
Aulos Bioscience continues to enroll patients in its Phase 2 expansion cohorts, evaluating imneskibart in CPI-refractory melanoma and NSCLC. The company aims to present comprehensive clinical data by mid-2026, potentially leading to regulatory approval and commercialization. Further research will focus on optimizing imneskibart's application across various cancer types, enhancing its impact on cancer treatment.
